Prot #MK-3475-122: A Two-Arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)

Project: Research project

Project Details

StatusActive
Effective start/end date1/26/17 → 1/31/25

Funding

  • Merck Sharp & Dohme Corporation (Prot #MK-3475-122)